| Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug R Capdeville, E Buchdunger, J Zimmermann, A Matter Nature reviews Drug discovery 1 (7), 493-502, 2002 | 1810 | 2002 |
| A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity T Meyer, U Regenass, D Fabbro, E Alteri, J Röusel, M Möller, G Caravatti, ... International journal of cancer 43 (5), 851-856, 1989 | 552 | 1989 |
| Wnt addiction of genetically defined cancers reversed by PORCN inhibition B Madan, Z Ke, N Harmston, SY Ho, AO Frois, J Alam, DA Jeyaraj, ... Oncogene 35 (17), 2197-2207, 2016 | 291 | 2016 |
| Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients. U Eppenberger, W Kueng, JM Schlaeppi, JL Roesel, C Benz, H Mueller, ... Journal of clinical oncology 16 (9), 3129-3136, 1998 | 276 | 1998 |
| Tumor angiogenesis as a therapeutic target A Matter Drug Discovery Today 6 (19), 1005-1024, 2001 | 191 | 2001 |
| MOUSE THYMUS-INDEPENDENT AND THYMUS-DERIVED LYMPHOID CELLS: I. IMMUNOFLUORESCENT AND FUNCTIONAL STUDIES JP Lamelin, B Lisowska-Bernstein, A Matter, JE Ryser, P Vassalli The Journal of Experimental Medicine 136 (5), 984-1007, 1972 | 173 | 1972 |
| Homo-and heterocellular junctions in cell cultures: an electrophysiological and morphological study A Hyde, B Blondel, A Matter, JP Cheneval, B Filloux, L Girardier Progress in brain research 31, 283-311, 1969 | 172 | 1969 |
| Microcinematographic and electron microscopic analysis of target cell lysis induced by cytotoxic T lymphocytes. A Matter Immunology 36 (2), 179, 1979 | 163 | 1979 |
| A study on permeability barriers between Disse space and bile canaliculus A Matter J. Ultrastruct. Res. 1, 1969 | 163 | 1969 |
| Protein tyrosine kinase inhibitors: new treatment modalities? D Fabbro, D Parkinson, A Matter Current opinion in pharmacology 2 (4), 374-381, 2002 | 157 | 2002 |
| From vitamin A to retinoids in experimental and clinical oncology: achievements, failures, and outlook W Bollag, A Matter Annals of the New York Academy of Sciences 359 (1), 9-23, 1981 | 150 | 1981 |
| Bcr-Abl inhibition as a modality of CML therapeutics. E Buchdunger, A Matter, BJ Druker Biochimica et Biophysica Acta 1551 (1), M11-8, 2001 | 147 | 2001 |
| CGS 16949A, a New Nonsteroidal Aromatase Inhibitor: Effects on Hormone-dependent and -independent Tumors in Vivo K Schieweck, AS Bhatnagar, A Matter Cancer research 48 (4), 834-838, 1988 | 119 | 1988 |
| Liver‐colonizing melanoma cells selected from B‐16 melanoma TW Tao, A Matter, K Vogel, MM Burger International Journal of Cancer 23 (6), 854-857, 1979 | 115 | 1979 |
| Anti‐tumor effects of tumor necrosis factor in combination with chemotherapeutic agents U Regenass, M Müller, E Curschellas, A Matter International journal of cancer 39 (2), 266-273, 1987 | 102 | 1987 |
| MOUSE THYMUS-INDEPENDENT AND THYMUS-DERIVED LYMPHOID CELLS: II. ULTRASTRUCTURAL STUDIES A Matter, B Lisowska-Bernstein, JE Ryser, JP Lamelin, P Vassalli The Journal of Experimental Medicine 136 (5), 1008-1030, 1972 | 99 | 1972 |
| Rescue of oxytocin response and social behaviour in a mouse model of autism H Hörnberg, E Perez-Garci, D Schreiner, L Hatstatt-Burklé, F Magara, ... Nature 584 (7820), 252-256, 2020 | 88 | 2020 |
| A morphometric study on the nexus of rat cardiac muscle A Matter The Journal of Cell Biology 56 (3), 690-696, 1973 | 81 | 1973 |
| Cytogenetics of breast cancer D Geleick, H Müller, A Matter, J Torhorst, U Regenass Cancer genetics and cytogenetics 46 (2), 217-229, 1990 | 80 | 1990 |
| New S-Adenosylmethionine Decarboxylase Inhibitors with Potent Antitumor Activity U Regenass, G Caravatti, H Mett, J Stanek, P Schneider, M Müller, ... Cancer Research 52 (17), 4712-4718, 1992 | 77 | 1992 |
